PharmaMar, S.A.

There is expected to be activity at the European Medicines Agency this week regarding the re-evaluation of PharmaMar’s EU marketing application for Aplidin (plitidepsin), which was rejected in 2018 in

In a shot at repeating Daiichi Sankyo Co., Ltd. ’s hugely successful development of deruxtecan as a cytotoxic payload, the holy grail in the design of antibody-drug conjugates (ADCs), Singapore-based

The Phase III trial of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd. ’s ifinatamab deruxtecan (I-DXd) in small-cell lung cancer (SCLC) will report in 2027, and following the recent misfire with an

At first glance, the curious thing about the failure of Sylentis S.A.U. ’s tivanisiran in a Phase III trial in dry-eye disease associated with Sjögren’s syndrome is that it follows a late-stage hit i